About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 831907, 7 pages
http://dx.doi.org/10.1155/2013/831907
Clinical Study

Prognostic Significance of Immunohistochemical Phenotypes in Patients Treated for High-Grade Cervical Intraepithelial Neoplasia

1Department of Gynecology & Obstetrics, Vita-Salute San Raffaele University, School of Medicine at San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
2Department of Pathology, Vita-Salute San Raffaele University, School of Medicine at San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy

Received 21 April 2013; Revised 2 October 2013; Accepted 4 October 2013

Academic Editor: Martin Bornhaeuser

Copyright © 2013 Massimo Origoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Soerjomataram, J. Lortet-Tieulent, D. M. Parkin et al., “Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions,” The Lancet, vol. 380, no. 9856, pp. 1840–1850, 2012. View at Publisher · View at Google Scholar
  2. H. zur Hausen, “Papillomaviruses and cancer: from basic studies to clinical application,” Nature Reviews Cancer, vol. 2, no. 5, pp. 342–350, 2002. View at Scopus
  3. F. X. Bosch, M. M. Manos, N. Munoz et al., “Prevalence of human papillomavirus in cervical cancer: a worldwide perspective,” Journal of the National Cancer Institute, vol. 87, no. 11, pp. 796–802, 1995. View at Scopus
  4. M. Schiffman and N. Wentzensen, “Human Papillomavirus infection and the multistage carcinogenesis of cervical cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 4, pp. 553–560, 2013. View at Publisher · View at Google Scholar
  5. M. Evander, K. Edlund, A. Gustafsson et al., “Human papillomavirus infection is transient in young women: a population- based cohort study,” Journal of Infectious Diseases, vol. 171, no. 4, pp. 1026–1030, 1995. View at Scopus
  6. G. Y. F. Ho, R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk, “Natural history of cervicovaginal papillomavirus infection in young women,” The New England Journal of Medicine, vol. 338, no. 7, pp. 423–428, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Schiffman, P. E. Castle, J. Jeronimo, A. C. Rodriguez, and S. Wacholder, “Human papillomavirus and cervical cancer,” The Lancet, vol. 370, no. 9590, pp. 890–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. W. Tindle, “Immune evasion in human papillomavirus-associated cervical cancer,” Nature Reviews Cancer, vol. 2, no. 1, pp. 59–65, 2002. View at Scopus
  9. M. H. Hibma, “The immune response to Papillomavirus during infection persistence and regression,” The Open Virology Journal, vol. 6, supplement 2, pp. 241–248, 2012. View at Publisher · View at Google Scholar
  10. T. Sasagawa, H. Takagi S, and S. Makinoda, “Immune responses against Human Papillomavirus (HPV) infection and evasion of host defense on cervical cancer,” Journal of Infection and Chemotherapy, vol. 18, no. 6, pp. 807–815, 2012. View at Publisher · View at Google Scholar
  11. K. U. Petry, D. Scheffel, U. Bode et al., “Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions,” International Journal of Cancer, vol. 57, no. 6, pp. 836–840, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Serraino, P. Carrieri, C. Pradier, et al., “Risk of invasive cervical cancer among women with, or at risk for, HIV infection,” International Journal of Cancer, vol. 82, no. 3, pp. 334–337, 1999.
  13. M. I. Alloub, B. B. B. Barr, K. M. McLaren, I. W. Smith, W. H. Bunney, and G. E. Smart, “Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts,” British Medical Journal, vol. 298, no. 6667, pp. 153–156, 1989. View at Scopus
  14. F. B. Lillo, D. Ferrari, F. Veglia et al., “Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 184, no. 5, pp. 547–551, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Uberti-Foppa, M. Origoni, M. Maillard et al., “Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women,” Journal of Medical Virology, vol. 56, no. 2, pp. 133–137, 1998.
  16. C. K. Fairley, S. Chen, S. N. Tabrizi et al., “Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment,” Nephrology Dialysis Transplantation, vol. 9, no. 4, pp. 416–420, 1994. View at Scopus
  17. A. Carus, M. Ladekarl, B. S. Nedergaard, and F. Donskov, “Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localized cervical cancer,” British Journal of Cancer, vol. 108, pp. 2116–2122, 2013. View at Publisher · View at Google Scholar
  18. P. J. de Vos van Steenwijk, T. H. Ramwadhdoebe, R. Goedemans et al., “Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma,” International Journal of Cancer, vol. 133, no. 12, pp. 2884–2894, 2013. View at Publisher · View at Google Scholar
  19. S. J. Piersma, E. S. Jordanova, M. I. E. van Poelgeest et al., “High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer,” Cancer Research, vol. 67, no. 1, pp. 354–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Konya and J. Dillner, “Immunity to oncogenic human papillomaviruses,” Advances in Cancer Research, vol. 82, pp. 205–238, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Evans, L. K. Borysiewicz, A. S. Evans et al., “Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6,” Journal of Immunology, vol. 167, no. 9, pp. 5420–5428, 2001. View at Scopus
  22. S. L. Giannini, P. Hubert, J. Doyen, J. Boniver, and P. Delvenne, “Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix,” International Journal of Cancer, vol. 97, no. 5, pp. 654–659, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Manickam, M. Sivanandham, and I. L. Tourkova, “Immunological role of dendritic cells in cervical cancer,” Advances in Experimental Medicine and Biology, vol. 601, pp. 155–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-J. Um, J.-W. Rhyu, E.-J. Kim, K.-C. Jeon, E.-S. Hwang, and J.-S. Park, “Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo,” Cancer Letters, vol. 179, no. 2, pp. 205–212, 2002. View at Scopus
  25. S. Monnier-Benoit, F. Mauny, D. Riethmuller et al., “Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix,” Gynecologic Oncology, vol. 102, no. 1, pp. 22–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. H. J. Bontkes, T. D. de Gruijl, and A. I. C. van der Muysemberg, “Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia,” International Journal of Cancer, vol. 88, no. 1, pp. 92–98, 2000.
  27. A. de Jong, S. H. van der Burg, K. M. C. Kwappenberg et al., “Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects,” Cancer Research, vol. 62, no. 2, pp. 472–479, 2002. View at Scopus
  28. N. Coleman, H. D. L. Birley, A. M. Renton et al., “Immunological events in regressing genital warts,” American Journal of Clinical Pathology, vol. 102, no. 6, pp. 768–774, 1994. View at Scopus
  29. K. Hong, C. E. Greer, N. Ketter, G. van Nest, and X. Paliard, “Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts,” Journal of Virology, vol. 71, no. 9, pp. 6427–6432, 1997. View at Scopus
  30. M. Origoni, P. Cristoforoni, S. Costa, L. Mariani, P. Scirpa, and A. Lorincz M, “HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice,” Ecancermedicalscience, vol. 6, article 258, 2012. View at Publisher · View at Google Scholar
  31. L. Mariani, M. Sideri, S. Costa, P. Cristoforoni, M. Origoni, and M. Preti, “Human papillomavirus DNA and Pap tests: the need for cotesting in opportunistic setting during the transition time,” Journal of Lower Genital Tract Disease, vol. 17, no. 3, pp. 362–365, 2013. View at Publisher · View at Google Scholar
  32. M. Origoni, G. Carminati, S. Rolla et al., “Human papillomavirus viral load expressed as Relative Light Units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in Atypical Squamous Cells of Undetermined Significance (ASCUS) cytology,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 31, no. 9, pp. 2401–2406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Origoni, G. Carminati, M. Sideri, M. Clementi, S. Rolla, and M. Candiani, “‘Low-grade positivity’ of HPV viral load after Atypical Squamous Cells of Undetermined Significance (ASC-US) cytology identifies women at low-risk for cervical intraepithelial neoplasia grade 2 and 3,” European Journal of Gynaecological Oncology, vol. 33, no. 3, pp. 261–264, 2012.
  34. M. Origoni, “High viral load identifies cervical lesions—letter,” Cancer Epidemiology Biomarkers & Prevention, vol. 22, no. 10, article 1924, 2013. View at Publisher · View at Google Scholar
  35. J. M. M. Walboomers, M. V. Jacobs, M. M. Manos et al., “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide,” Journal of Pathology, vol. 189, pp. 12–19, 1999.
  36. A.-B. Moscicki, M. Schiffman, S. Kjaer, and L. L. Villa, “Chapter 5: updating the natural history of HPV and anogenital cancer,” Vaccine, vol. 24, no. 3, pp. S42–S51, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. M. Parkin and F. Bray, “Chapter 2: the burden of HPV-related cancers,” Vaccine, vol. 24, no. 3, pp. S11–S25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Y. Tjiong, T. A. Out, J. Ter Schegget, M. P. M. Burger, and N. Van der Vange, “Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review,” International Journal of Gynecological Cancer, vol. 11, no. 1, pp. 9–17, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Ferenczy, F. Coutlée, E. Franco, and C. Hankins, “Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments,” Canadian Medical Association Journal, vol. 169, no. 5, pp. 431–434, 2003. View at Scopus
  40. M. Origoni, C. Stefani, G. Dell'Antonio, G. Carminati, M. Parma, and M. Candiani, “Cervical human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study,” Journal of Clinical Virology, vol. 51, no. 4, pp. 250–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. D. H. Schuurhuis, N. Fu, F. Ossendorp, and C. J. M. Melief, “Ins and outs of dendritic cells,” International Archives of Allergy and Immunology, vol. 140, no. 1, pp. 53–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Banchereau, F. Briere, C. Caux et al., “Immunobiology of dendritic cells,” Annual Review of Immunology, vol. 18, pp. 767–811, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. S. C. Fausch, D. M. Da Silva, M. P. Rudolf, and W. M. Kast, “Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses,” Journal of Immunology, vol. 169, no. 6, pp. 3242–3249, 2002. View at Scopus
  44. I. C. Le Poole, W. M. ElMasri, C. J. Denman et al., “Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells,” Cancer Immunology, Immunotherapy, vol. 57, no. 6, pp. 789–797, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. A. de Jong, M. I. E. van Poelgeest, J. M. Van der Hulst et al., “Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6,” Cancer Research, vol. 64, no. 15, pp. 5449–5455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. D. E. Warrino, W. C. Olson, W. T. Knapp et al., “Disease-stage variance in functional CD4+ T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes,” Clinical Cancer Research, vol. 10, no. 10, pp. 3301–3308, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Seresini, M. Origoni, F. Lillo et al., “IFN-γ produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions,” Journal of Immunology, vol. 179, no. 10, pp. 7176–7183, 2007. View at Scopus
  48. R. D. M. Steenbergen, V. E. OudeEngberink, D. Kramer et al., “Down-regulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis,” American Journal of Pathology, vol. 160, no. 6, pp. 1945–1951, 2002. View at Scopus